Mettis Global’s Post

🌍 Exciting Progress in COPD Treatment! GSK has announced positive results from their phase III trial of Nucala (mepolizumab) for patients with chronic obstructive pulmonary disease (COPD). The MATINEE trial showed a clinically meaningful reduction in moderate/severe exacerbations when Nucala was added to standard inhaled maintenance therapy. 🌟 COPD affects over 300 million people globally, and around 40% of patients experience type 2 inflammation—driven by IL-5 cytokines—which can lead to severe exacerbations and hospitalizations. By targeting IL-5, Nucala has shown potential to significantly improve outcomes for COPD patients with raised eosinophil counts. This is a promising development for the future of respiratory treatments, and I look forward to seeing the full trial results at an upcoming scientific congress! #Healthcare #Pharma #COPD #ClinicalTrials #Nucala #GSK

The FDA has given the green light to Alexion's Ultomiris offering hope to adult neuromyelitis optica spectrum disorder with AQP4 antibody-positive forms of the disease. A key victory, marking it as the fourth approved treatment option. 🙌 This groundbreaking therapy offers a new lease on life every two months with its infusion schedule - a comforting shift from the previous fortnightly routine. Patients can now breathe a sigh of relief with this more manageable approach to preventing NMOSD relapses. With a robust phase 3 trial showcasing zero relapses, Ultomiris is an incredible milestone for NMOSD patients. #Astrazeneca #AlexionPharmaceuticals #FDAapproval #RareDisease #Ultomiris #AstraZeneca #NMOSD

Durvalumab Treatment Regimen Reduces Risk of Disease Progression, Death in Patients With HCC: Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS. #finance #pharmacy #lifesciences

𝐅𝐃𝐀 𝐚𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐈𝐦𝐞𝐭𝐞𝐥𝐬𝐭𝐚𝐭 𝐟𝐨𝐫 𝐥𝐨𝐰- 𝐭𝐨 𝐢𝐧𝐭𝐞𝐫𝐦𝐞𝐝𝐢𝐚𝐭𝐞-1 𝐫𝐢𝐬𝐤 𝐦𝐲𝐞𝐥𝐨𝐝𝐲𝐬𝐩𝐥𝐚𝐬𝐭𝐢𝐜 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞𝐬 𝐰𝐢𝐭𝐡 𝐭𝐫𝐚𝐧𝐬𝐟𝐮𝐬𝐢𝐨𝐧-𝐝𝐞𝐩𝐞𝐧𝐝𝐞𝐧𝐭 𝐚𝐧𝐞𝐦𝐢𝐚 👉 The FDA approved 𝐈𝐦𝐞𝐭𝐞𝐥𝐬𝐭𝐚𝐭 (𝐑𝐲𝐭𝐞𝐥𝐨), an 𝐨𝐥𝐢𝐠𝐨𝐧𝐮𝐜𝐥𝐞𝐨𝐭𝐢𝐝𝐞 𝐭𝐞𝐥𝐨𝐦𝐞𝐫𝐚𝐬𝐞 𝐢𝐧𝐡𝐢𝐛𝐢𝐭𝐨𝐫, for adults with low- to intermediate-1 risk 𝐦𝐲𝐞𝐥𝐨𝐝𝐲𝐬𝐩𝐥𝐚𝐬𝐭𝐢𝐜 𝐬𝐲𝐧𝐝𝐫𝐨𝐦𝐞𝐬 (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs) 👉 The recommended imetelstat dosage is 7.1 𝐦𝐠/𝐤𝐠 administered as an I.V. infusion over 2 hrs/4 wks 👉 The approval was based on results from the 𝐈𝐌𝐞𝐫𝐠𝐞 𝐏𝐡3 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐭𝐫𝐢𝐚𝐥, published in The Lancet 4 👉 The IMerge trial met its primary and key secondary endpoints, with RYTELO demonstrating significantly higher rates of red blood cell transfusion independence (RBC-TI) versus placebo for atleast 8 consecutive weeks and for at least 24 weeks 👉 The safety profile of RYTELO was well-characterized with generally manageable and short-lived thrombocytopenia and neutropenia 👉 Geron aims to ensure broad access to RYTELO for eligible patients through its 𝐑𝐄𝐀𝐂𝐇4𝐑𝐘𝐓𝐄𝐋𝐎 Patient Support Program that will provide a range of resources that support 𝐚𝐜𝐜𝐞𝐬𝐬 and 𝐚𝐟𝐟𝐨𝐫𝐝𝐚𝐛𝐢𝐥𝐢𝐭𝐲 to eligible patients prescribed RYTELO

Novartis Reveals the P-IIIb (V-INITIATE) Trial Results of Leqvio for Treating Atherosclerotic Cardiovascular Disease (ASCVD) #novartis #leqvio #atheroscleroticcardiovasculardisease #clinicaltrial #phase3b #safety #efficacy #treatment #vinitiate #orion3 #orion8

Inclisiran is a gene-based injectable drug, administered every 6 months, to lower LDL-cholesterol. It is approved for use in adults with #hypercholesterolaemia or atherosclerotic cardiovascular disease, or who are at high risk of #cardiovascular disease. It is an alternative treatment option (or can be used in combination with) other lipid-lowering medicines for patients on a maximum tolerated dose of a statin or who are statin intolerant. Read the review: https://lnkd.in/gRxra387

🎉 The June issue of Australian Prescriber has been published 🎉 This issue is particularly special as it is the first one I had the privilege of working on since joining the team as an #editor a couple of months ago. I have been learning so much, and am proud of the collaborative effort that has gone into producing high-quality articles and updates for our readers. Be sure to check it out! 📖 https://lnkd.in/g8QCE8qA #AustralianPrescriber #journal #drugs #therapeutics Therapeutic Guidelines

Double Dupi Update: - chronic spontaneous urticaria patients in the confirmatory phase 3 LIBERTY-CUPID Study C trial achieved nearly 50% more itch and activity reduction compared to placebo with 30% achieving complete response by week 24 - 41% of bullous pemphigoid patients in the ADEPT phase 2/3 trial achieved at least 90% improvement in disease severity with 20% achieving complete clinical remission with the discontinuation of oral corticosteroids by week 16, without relapse or need for rescue therapy during the 36-week treatment period Looking forward to having additional options for these often difficult to treat conditions! #dupilumab #chronicspontaneousurticaria #CSU #bullouspemphigoid #BP https://lnkd.in/eiRe8wHV https://lnkd.in/erYUqYzq

The #PriorityReviewVoucher (#PRV) program, specifically aimed at incentivizing drug development for #rarepediatricdiseases, is facing uncertainty regarding its future beyond September. Under the program, companies that successfully develop drugs for qualifying rare pediatric diseases can receive PRVs, which are intended to encourage pharmaceutical companies to invest in research for these less commercially viable conditions. According to the National Organization for Rare Disorders (#NORD), since the program's inception there have been 53 PRVs awarded for 39 pediatric rare diseases, suggesting an increase in drug development efforts. The program will need to be renewed by #Congress, but the decision comes amidst concerns about its effectiveness and is compounded by a busy legislative schedule. The reauthorization efforts for the PRV program have bipartisan support in Congress, indicating recognition of its potential benefits and the importance of continuing incentives for rare pediatric disease research. The development of therapies for #rarediseases has seen significant progress in recent years, but even today there are still many patients suffering from limited treatment options. The industry must continue to foster these efforts wherever possible to avoid a plateau in progress in this area of significant unmet need

Ten years ago today (October 15, 2014), the FDA approved the first two treatments for a rare, fatal lung condition called Idiopathic Pulmonary Fibrosis. Those first two treatments, ESBRIET (pirfenidone) and OFEV (nintedanib), were launched by two companies that worked with the IPF community for years to secure approval. During this first decade of antifibrotics, thousands of US IPF patients have been able to benefit from these therapies. Real people have had better lives because of these medicines. For my friends and colleagues at InterMune / Genentech who worked on ESBRIET, you each played a role to help achieve this important milestone for patients. But we haven't achieved the ultimate goal yet. Every IPF patient deserves the chance to have stable lung function and to live a normal life. We need new treatments that can help patients in different ways, because unfortunately IPF is still a very challenging and scary disease for patients. Let's hope the next decade brings even more new treatments for IPF, so that all IPF patients are able to live the life they want. They deserve it.